Malaria drug cures coronavirus patients as vaccine trial begins

A new controlled clinical study conducted by doctors in France shows that hydroxychloroquine cures 100% of coronavirus patients within 6 days of treatment.

Researchers are cautiously optimistic that the old malaria and autoimmune drug, manufactured under the brand name Plaquenil, could bring relief to victims of the pandemic based on ongoing clinical trials.

The drug, which was approved in 1955, is being viewed as a quick, safe and economical way to treat hundreds of thousands of coronavirus victims around the world, saving lives.

The findings of the study were released on the website covidtrial.io. The study was recently accepted to the International Journal of Antimicrobial Agents by Elsevier.

 It was presented by Thomas R. Broker, (Stanford PhD), James M. Todaro (Columbia MD), and Gregory J. Rigano, Esq., in consultation with Stanford University School of Medicine, UAB School of Medicine, and National Academy of Sciences researchers.

The White House Coronavirus Task Force has been studying the drug and a number of others as cases in the U.S. soar to 10,919 with 163 deaths.

President Donald Trump announced Thursday that hydroxychloroquine would be made available almost immediately to treat coronavirus.

“It’s been around for a long time, so we know if things don’t go as planned, it’s not going to kill anybody,” Trump told reporters at the White House.

He said it was a common drug and would soon be available for “prescribed use” on coronavirus, calling it a “game-changer.”

“We have to remove every barrier or a lot of barriers that were unnecessary and they’ve done that to get the rapid deployment of safe, effective treatments and we think we have some good answers,” Trump said.

“So we slashed red tape to develop vaccines and therapies as fast as it can possibly be done, long before anybody else was even thinking about doing this. As you know, earlier this week we began the first clinical trial of a vaccine candidate for the virus,” Trump added.

He discussed the clinical trials underway for new coronavirus therapies “scaling these to allow many more Americans to access different drugs that have shown really good promise.”

“We’ve had some really good promise. We will do so in a way that lets us continue to collect the data to know when,” Trump said.

“We have a couple that we’re in really good shape on. And that’s for immediate delivery. Immediate, like as fast as we can get it. The FDA has also approved compassionate use for a significant number of patients,” the president said.

The coronavirus pandemic has so far claimed 9,389 lives worldwide, with at least 230,496 cases reported and 86,256 people recovered.

Adviser to Stanford University School of Medicine Gregory Rigano appeared on the Fox News show Tucker Carlson Tonight on Wednesday to announce the findings of the hydroxychloroquine study.

“Hydroxychloroquine has been in the market for over 50 years with a quality safety profile, and I’m here to report that as of this morning, about five o’clock this morning, a well-controlled peer reviewed study carried out by the most eminent Infectious Disease specialist in the world, Didier Raoult, MD, PhD, out of the south of France, in which he enrolled 40 patients, again a well-controlled peer reviewed study that showed a 100 percent cure rate against coronavirus,” said Rigano.

He explained that “to be able to cure a virus was said to be mathematically impossible and the first company that did it was a small biotech called PharmaSet that was acquired by Gilead Sciences in the cure to hepatitis C. What we’re here to announce is the second cure to a virus of all time.”

According to research by the Centers for Disease Control, chloroquine has strong antiviral effects on SARS coronavirus, both prophylactically and therapeutically. SARS coronavirus has significant similarities to COVID-19.